These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 25764276)

  • 21. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
    Maniv I; Jiang W; Bikard D; Marraffini LA
    J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approaches to study CRISPR RNA biogenesis and the key players involved.
    Behler J; Hess WR
    Methods; 2020 Feb; 172():12-26. PubMed ID: 31325492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purification and characterization of ribonucleoprotein effector complexes of Sulfolobus islandicus CRISPR-Cas systems.
    Feng M; She Q
    Methods Enzymol; 2021; 659():327-347. PubMed ID: 34752293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Foreign DNA acquisition by the I-F CRISPR-Cas system requires all components of the interference machinery.
    Vorontsova D; Datsenko KA; Medvedeva S; Bondy-Denomy J; Savitskaya EE; Pougach K; Logacheva M; Wiedenheft B; Davidson AR; Severinov K; Semenova E
    Nucleic Acids Res; 2015 Dec; 43(22):10848-60. PubMed ID: 26586803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly efficient primed spacer acquisition from targets destroyed by the Escherichia coli type I-E CRISPR-Cas interfering complex.
    Semenova E; Savitskaya E; Musharova O; Strotskaya A; Vorontsova D; Datsenko KA; Logacheva MD; Severinov K
    Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7626-31. PubMed ID: 27325762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA interference is controlled by R-loop length in a type I-F1 CRISPR-Cas system.
    Tuminauskaite D; Norkunaite D; Fiodorovaite M; Tumas S; Songailiene I; Tamulaitiene G; Sinkunas T
    BMC Biol; 2020 Jun; 18(1):65. PubMed ID: 32539804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining the Specificity of Cascade Binding, Interference, and Primed Adaptation
    Cooper LA; Stringer AM; Wade JT
    mBio; 2018 Apr; 9(2):. PubMed ID: 29666291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR-Cas System: The Powerful Modulator of Accessory Genomes in Prokaryotes.
    Butiuc-Keul A; Farkas A; Carpa R; Iordache D
    Microb Physiol; 2022; 32(1-2):2-17. PubMed ID: 34192695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioinformatic evidence of widespread priming in type I and II CRISPR-Cas systems.
    Nicholson TJ; Jackson SA; Croft BI; Staals RHJ; Fineran PC; Brown CM
    RNA Biol; 2019 Apr; 16(4):566-576. PubMed ID: 30157725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptome changes in STSV2-infected Sulfolobus islandicus REY15A undergoing continuous CRISPR spacer acquisition.
    León-Sobrino C; Kot WP; Garrett RA
    Mol Microbiol; 2016 Feb; 99(4):719-28. PubMed ID: 26514343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR-spacer integration reporter plasmids reveal distinct genuine acquisition specificities among CRISPR-Cas I-E variants of Escherichia coli.
    Díez-Villaseñor C; Guzmán NM; Almendros C; García-Martínez J; Mojica FJ
    RNA Biol; 2013 May; 10(5):792-802. PubMed ID: 23445770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protospacer recognition motifs: mixed identities and functional diversity.
    Shah SA; Erdmann S; Mojica FJ; Garrett RA
    RNA Biol; 2013 May; 10(5):891-9. PubMed ID: 23403393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different modes of spacer acquisition by the Staphylococcus epidermidis type III-A CRISPR-Cas system.
    Aviram N; Thornal AN; Zeevi D; Marraffini LA
    Nucleic Acids Res; 2022 Feb; 50(3):1661-1672. PubMed ID: 35048966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mobile Genetic Elements and Evolution of CRISPR-Cas Systems: All the Way There and Back.
    Koonin EV; Makarova KS
    Genome Biol Evol; 2017 Oct; 9(10):2812-2825. PubMed ID: 28985291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems.
    Makarova KS; Aravind L; Wolf YI; Koonin EV
    Biol Direct; 2011 Jul; 6():38. PubMed ID: 21756346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative CRISPR type III-based knockdown of essential genes in hyperthermophilic
    Zink IA; Fouqueau T; Tarrason Risa G; Werner F; Baum B; Bläsi U; Schleper C
    RNA Biol; 2021 Mar; 18(3):421-434. PubMed ID: 32957821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR-Cas: Complex Functional Networks and Multiple Roles beyond Adaptive Immunity.
    Faure G; Makarova KS; Koonin EV
    J Mol Biol; 2019 Jan; 431(1):3-20. PubMed ID: 30193985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural basis of CRISPR-Cas Type III prokaryotic defence systems.
    Molina R; Sofos N; Montoya G
    Curr Opin Struct Biol; 2020 Dec; 65():119-129. PubMed ID: 32712502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems.
    Mohanraju P; Makarova KS; Zetsche B; Zhang F; Koonin EV; van der Oost J
    Science; 2016 Aug; 353(6299):aad5147. PubMed ID: 27493190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.